

Kai Yeung

PharmD, PhD

1730 Minor Ave, Ste 1600
Seattle, WA 98101

Office: (206) 287-2063
Kai.Yeung@kp.org

EDUCATIONAL AND BIOGRAPHICAL INFORMATION

| | |
|---|-----------------------------|
| Doctor of Philosophy in Pharmaceutical Outcomes Research & Policy University Washington Dissertation title: Does Cost-Effectiveness Analysis Have a Role in US Managed Care Drug Formularies? Empirical Study of Utilization, Costs, Outcomes and Elasticity in a Value-Based Formulary Dissertation Committee: Sean Sullivan (chair), Anirban Basu, Ryan Hansen and John Watkins | Dec 2015 Seattle, WA |
| Doctor of Pharmacy University of Southern California | May 2011 Los Angeles, CA |
| Masters of Science in Biology University of California, San Diego | Feb 2005 La Jolla, CA |
| Bachelors of Science in Biology University of California, San Diego | Jun 2003 La Jolla, CA |
| Pharmacist License California Lic.#: RPH 66494 Washington Lic.#: PH 60231957 | |

PROFESSIONAL POSITIONS

| | |
|---|-------------------------------------|
| Assistant Scientific Investigator Kaiser Permanente Washington Health Research Institute (Formerly Group Health Research Institute) | Aug 2016- Present Seattle, WA |
| Assistant Professor Kaiser Permanente Bernard J. Tyson School of Medicine | Sept 2019- Present Seattle, WA |
| Affiliate Assistant Professor School of Pharmacy, University Washington | June 2017- Present Seattle, WA |
| Post-doctoral Research Fellow Pharmaceutical Outcomes Research & Policy, University Washington | Sept 2015- Sept 2016 Seattle, WA |
| Predocctoral Research Associate Pharmaceutical Outcomes Research & Policy, University Washington | Sept 2011- Aug 2015 Seattle, WA |
| Cost-Effectiveness Registry Reader Tufts Medical Center Institute for Clinical Research and Health Policy Studies | Mar 2010- June 2013 Boston, MA |

| | |
|--|---|
| Visiting Researcher National Institute for Health and Clinical Excellence | Yeung, K May 2011- Aug 2011 London, UK |
| Research Intern The Food and Drug Administration | Mar 2011- May 2011 Silver Spring, MD |
| Program Analyst Agency for Healthcare Research and Quality | June 2010- Aug 2010 Rockville, MD |
| AMCP/FMCP/Allergan Specialized Health Outcomes Summer Intern Allergan Global Health Outcomes Strategy and Research Wellpoint Clinical Analytic Strategies | June 2009- Aug 2009 Irvine, CA West Hills, CA |
| Marketing Research Consultant OrthoAlign Inc. | Oct 2009- July 2010 Aliso Viejo, CA |
| Drug Information/Pharmacy Outcomes Research Intern Kaiser Permanente | Jan 2008- July 2010 Downey, CA |
| Volunteer Consultation Pharmacy Intern Weingart Medical Clinic/ LA County Hospital Liver Clinic | Dec 2008- May 2008 Los Angeles, CA |
| Research Assistant Broad Center for Regenerative Medicine | May 2008- Aug 2008 Los Angeles, CA |
| Research Associate University of California San Diego | Jul 2003- Feb 2005 La Jolla, CA |

PROFESSIONAL HONORS

| | |
|--|------------|
| Multiple Chronic Conditions Scholar HCSRN-OAIC AGING Initiative (supported by the National Institute on Aging) | Feb 2021 |
| Butler-Williams Scholar in Aging Research National Institute on Aging | June 2020 |
| Best Paper of the Year Journal of Managed Care & Specialty Pharmacy | April 2018 |
| Best Paper Challenge Prize: First Place American Journal of Managed Care and Patient Access Network Challenge | Jan 2017 |
| Best Student Paper of the Year Vancouver Health Economics Methodology (VanHEM) Annual Meeting | June 2016 |
| Honorable Mention Best Paper of the Year Journal of Managed Care & Specialty Pharmacy | April 2016 |
| Best Student Podium Presentation | May 2015 |

International Society for Pharmacoeconomics and Outcomes Research

Best Student Podium Presentation

International Society for Pharmacoeconomics and Outcomes Research

June 2014

Bayer Endowed Academic Scholarship

University of Washington

Sept 2011-June 2013

Best Student Poster Presentation

Academy of Managed Care Pharmacists National Conference

Apr 2011

Jack Logan Converse Pharmacy Scholarship

University of California School of Pharmacy

Oct 2010

Best Pharmaceutical Industry Marketing & Development Plan

University of California School of Pharmacy

May 2010

University of Southern California Scholar

University of California School of Pharmacy

Sept 2008- May 2010

USA Funds Access to Education Scholarship

University of California School of Pharmacy

Sept 2007- May 2009

Rho Chi Academic Honor Society

University of California School of Pharmacy

Mar 2009

Who's Who Among Young Professionals

Cambridge, UK

May 2008

Phi Kappa Phi Honor Society

University of Southern California

Jan 2008

Charles W. Patrick Scholarship

San Diego City College

Awarded in recognition of service to the community

May 2007

Richard and Eloise Johnston Health Services Scholarship

San Diego Mesa College

Awarded in recognition of interest and potential as a Pharmacist

May 2007

Provost's Honors

University of California, San Diego

Awarded in recognition for nine quarters of GPA of 3.5 or higher

Jan 2000- June 2003

MEMBERSHIPS

AcademyHealth

Academy of Managed Care Pharmacy

American Society of Health Economists

International Society for Pharmacoeconomics and Outcomes Research

Society for Medical Decision Making

ORGANIZATIONAL SERVICE

| | |
|---|------------|
| Shark tank proposal review committee Kaiser Permanente Washington Health Research Institute | 2019 |
| Faculty search committee Kaiser Permanente Washington Health Research Institute | 2017- 2018 |

OTHER PROFESSIONAL SERVICE

| | |
|--|---------------|
| Adhoc Member- FDA Drug Safety and Risk Management Advisory Committee The Committee advises the Commissioner of Food and Drugs on risk management, risk communication, and quantitative evaluation of spontaneous reports for drugs | 2021- Present |
| Member- ISPOR Health Technology Assessment Council Examine challenges in the use of HTA in pluralistic healthcare systems | 2020- Present |
| Research Advisory Board member- Academy of Managed Care & Specialty Pharmacy | 2018- 2020 |
| President- ISPOR Student Chapter University of Washington | 2014- 2015 |
| PhD Admissions committee- Pharmaceutical Outcomes Research & Policy Program University of Washington | 2012- 2013 |

SPECIAL NATIONAL RESPONSIBILITIES

Not applicable.

EDITORIAL RESPONSIBILITIES

Peer reviewer- Annals of Internal Medicine, Health Affairs, the British Medical Journal, JAMA Internal Medicine
JAMA Health Forum, Canadian Medical Association Journal, Value in Health, Implementation Science,
Journal of Medical Economics, PLOS Medicine, Journal of Managed Care and Specialty Pharmacy
(High quality peer-reviewer award 2015, 2016, 2018, 2019)

Editorial Advisory Board Member- Journal of Managed Care & Specialty Pharmacy 2015- 2018

RESEARCH FUNDING

Funder: U.S. Food and Drug Administration (Contract)
PI: Bobbi Jo Yarborough, PsyD; Denise Boudreau, PhD
Role: Site Principal Investigator
Dates: 06/7/21-6/30/23
Title: Medication Use, Safety, and Evidence (MUSE) study
Goal: To estimate the prevalence and incidence of misuse, abuse, and addiction associated with long-term opioid treatment.
Funding: \$3 million

FTE: 20%
 Funder: Institute for Clinical and Economic Review (Contract)
 PI: Kai Yeung, PharmD, PhD
 Role: Principal Investigator
 Dates: 07/1/21-6/30/22
 Title: Evidence Author for Health Technology Assessment Report
 Goal: Lead development of the ICER health technology assessment reports.
 Funding: \$55,000
 FTE: 20%

Funder: NIH-National Institute of Diabetes and Digestive And Kidney Diseases (1R01DK125380-01)
 PI: David Arterburn, MD, MPH and Matthew Maciejewski PhD
 Role: Co-Investigator
 Dates: 07/17/20-3/31/24
 Title: Long-Term Costs and Return on Investment For Bariatric Surgery
 Goal: To estimate the long-term economic costs of bariatric surgery.
 Funding: \$853,402
 FTE: Year 1: 5%
 Year 2-5: 10%

Funder: NIH-National Institute on Drug Abuse (CTN-0074-A-1)
 PI: Sean Murphy, PhD
 Role: Site Principal Investigator
 Dates: 04/1/19-3/31/21
 Title: Primary care Opioid Use Disorders Treatment Trial (PROUD) Economics Ancillary Study
 Goal: To estimate the economic costs and benefits of primary care management of opioid use disorder in the PROUD trial.
 Funding: \$430,244
 FTE: 10%

Funder: NIH-National Institute on Aging (R01AG053221)
 PI: Michael Vitiello; Susan McCurry
 Role: Site Principal Investigator
 Dates: 09/1/16-04/30/21
 Title: Efficacy of scalable cognitive-behavioral therapy for insomnia in older adults with osteoarthritis pain
 Goal: Largest randomized trial to test telephone cognitive-behavioral therapy for insomnia and the first to evaluate its cost-effectiveness.
 Funding: \$684,077
 FTE: Year 4: 5%
 Year 5: 20%

Funder: The Donaghue Medical Research Foundation
 PI: Kai Yeung, PharmD, PhD
 Role: Principal Investigator
 Dates: 07/1/19-6/30/21
 Title: Value-based Formulary-Essentials: Testing and Expanding on Value in Prescription Drug Benefit Design
 Goal: To test a promising drug formulary that aligns patient out-of-pocket costs for drugs with the drugs' estimated value. We aim to evaluate the impact of the formulary on medication use, spending and other healthcare utilization.
 Funding: \$366,739
 FTE: 40%

Funder: Kaiser Permanente Washington Health Research Institute Development Fund

PI: Kai Yeung, PharmD, PhD
 Role: Principal Investigator
 Dates: 01/15/18-12/31/18
 Title: Impact of Medicare Transitions in the WA-All Payer Claims Dataset
 Goal: To generate preliminary evidence that targets the gaps in our understanding about the benefits and harms of Medicare transitions by characterizing the direction and magnitude of changes in medical and pharmacy benefits and provider networks that occur as a result of Medicare eligibility
 Funding: \$99,993
 FTE: 20%

Funder: Laura and John Arnold Foundation
 PI: Kai Yeung, PharmD, PhD
 Role: Principal Investigator
 Dates: 07/1/18-07/31/20
 Title: Aligning Patient and Health Plan Incentives to Improve Value in Pharmaceutical Care: a Patient Shared Savings Model
 Goal: To evaluate the impact of the real-world implementation of a patient shared savings program and its ability to address the use of higher value medications
 Funding: \$130,303
 FTE: 20%

Funder: Robert Wood Johnson Foundation
 PI: Kai Yeung, PharmD, PhD; Anirban Basu PhD
 Role: Co-Principal Investigator
 Dates: 01/15/18-1/14/19
 Title: Improving Access and Reducing Financial Burden for Patients on Specialty Drugs
 Goal: To investigate the economic impact of state-mandated limits on out-of-pocket cost sharing for specialty drugs
 Funding: \$139,582
 FTE: 26%

Funder: Biologics & Biosimilars Collective Intelligence Consortium
 PI: Jeffrey Brown, PhD
 Role: Site Principal Investigator
 Dates: 09/1/17-08/1/19
 Title: Biologics & Biosimilars Collective Intelligence Consortium Infrastructure and Task Orders
 Goal: To develop data infrastructure for comparative effectiveness and safety research on biologics and biosimilars using a multi-center distributed data model
 Funding: \$100,753
 FTE: 8%

Funder: Group Health Research Institute Development Fund
 PI: Kai Yeung, PharmD, PhD
 Role: Principal Investigator
 Dates: 01/1/17-12/31/17
 Title: Building a Cost Effectiveness Analysis and Modelling Resource for Group Health Research Institute
 Goal: Develop a Group Health biostatistician in cost-effectiveness and modelling methods to increase capacity for health economic research
 Funding: \$27,202
 FTE: 5%

Funder: Group Health Research Institute Development Fund
 PI: Beverly Green, MD, MPH

Role: Co-investigator
 Dates: 04/1/17-12/31/17
 Title: BP-CHECK Automated Office BP Measurements 2017 Development Fund Proposal
 Goal: To compare the cost- effectiveness of usual clinic BP, home BP, kiosk BP, automated office BPs, and 24 hour automated BP for diagnosis of hypertension
 Funding: \$30,235
 FTE: 5%

Funder: University of Washington, Program in Policy Research for Health Technologies
 PI: Louis Garrison, PhD
 Role: Post-doctoral Fellow
 Dates: 07/1/15-8/30/16
 Title: Paying for Cures and Other High-Cost, Breakthrough Treatments: Value, Affordability, Financing, and Policy Challenges
 Goal: To evaluate policy options to address the challenges of financing high cost, breakthrough interventions within health systems oriented to paying for chronic and low-cost acute treatments
 Funding: \$450,000
 FTE: 50%

Funder: Agency for Healthcare Research and Quality
 PI: Kai Yeung, PharmD
 Role: Principal Investigator
 Dates: 07/1/14-6/30/15
 Title: R36 HS23346-01A1: Incentivizing Value in Managed Care Plans: Impact of a Value-Based Formulary
 Goal: To evaluate the impact of a Value-Based Formulary on medication utilization, health services utilization, and expenditures.
 Funding: \$40,000
 FTE: 50%

Funder: NIH, National Center for Advancing Translational Sciences
 PI: Mary L. (Nora) Disis, MD
 Role: Trainee
 Dates: 07/1/13-6/30/14
 Title: TL1TR000422: Institute of Translational Sciences Pre-doctoral Training Program
 Goal: Intensive didactic coursework and mentored training in health economic methods.
 Role: Trainee
 Funding: \$69,000
 FTE: 50%

Funder: The Merck Foundation
 PI: Sean Sullivan, PhD
 Role: Trainee
 Dates: 06/12/12-6/21/13
 Title: Association of asthma control, cost and race
 Goal: To investigate whether partly and uncontrolled asthmas are associated with increased costs for asthma-related healthcare utilization compared to well-controlled asthma and to determine whether these associations differed across racial groups.
 Funding: \$200,000
 FTE: 10%

Funder: University of Washington
 PI: Sean Sullivan, PhD
 Role: Trainee
 Dates: 09/12/11-6/21/12

Title: Performance-Based Risk-Sharing Arrangements between Healthcare Payers and Medical Product Manufacturers
 Goal: To identify and characterize publicly available cases and related trends for performance-based arrangements.
 Funding: \$72,000
 FTE: 100%

Funder: University of California Graduate Student Research Grant
 PI: Kai Yeung, BS
 Role: Principal Investigator
 Dates: 01/01/2004-12/31/2004
 Title: Gender and Ploidy in Lycium
 Goal: To evaluate the association of chromosome number on self-incompatibility mechanisms in Lycium californicum
 Funding: \$1,500
 FTE: 0%

Funder: National Science Foundation Undergraduate Research Grant
 PI: Joshua Kohn, PhD
 Role: Trainee
 Dates: 05/15/2002-9/15/2002
 Title: Evolution of self-incompatibility in Solanaceae
 Goal: To assess the evolutionary diversity of the self-incompatibility gene in the Solanaceae family
 Funding: \$6,500
 FTE: 100%

TEACHING AND MENTORING RESPONSIBILITIES

| | |
|---|---------------------|
| Guest Lecturer for Cost-Effectiveness Analysis (30 students; 1.5 hr lecture) Drexel University, Philadelphia | May 2021 |
| Guest Lecturer for Methods in Pharmaceutical Policy Analysis (25 students; 1.5 hr lecture) University of Washington, Seattle | May 2021 |
| Guest Lecturer for Pharmacoepidemiology (30 students; 1 hr lecture) University of Washington, Seattle | May 2020 |
| Guest Lecturer for Special Studies in Managed Care Pharmacy (25 students; 1 hr lecture) University of Washington, Seattle | Nov 2019 |
| Course Instructor for PhD Independent Study (Elizabeth Brouwer) University of Washington, Seattle | June 2018- Dec 2018 |
| Guest Lecturer for Special Studies in Managed Care Pharmacy (25 students; 1 hr lecture) University of Washington, Seattle | Oct 2018 |
| Guest Lecturer for Special Studies in Managed Care Pharmacy | Oct 2017 |

(25 students; 1 hr lecture)
University of Washington, Seattle

Guest Lecturer for Clinical and Economic Evaluation in Managed Care Pharmacy Jan 2015
(30 students; 1 hr lecture)
University of Washington, Seattle

Mentor

University of Washington

- Yilin Chen (PhD student)
- Ernesto Ulloa (PhD student)
- Ryan Pistorisi (PharmD/MS student)
- Tania Kho (PharmD student)
- Ibrahim Khilfeh (PharmD student)

- Elizabeth Brouwer (PhD student)-dissertation committee member “Exploring the uptake of value-based formulary strategies and their application to specialty drugs”. Successful PhD Defense: 2020-2021

Sept 2013- Present
Seattle, WA

Kaiser Permanente Washington Health Research Institute

- Katrina Zywiec (PharmD resident)
- Kayne Mettert (PhD student and Research Support Specialist)

Nov 2017- July 2018
Seattle, WA

PUBLICATIONS

Published Papers in Peer-Reviewed Journals

1. Yilin Chen, Xu Ji, Xiao Hong, Yi Cai, Joseph M Unger, **Yeung K**. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls. *Front Pharmacol*. Nov 29, 2021. Epub ahead of print.
2. **Yeung K**, Ulloa E. Incentivizing Prescription Drug Switching to Reduce Patient and Health Plan Spending: A Microsimulation Model. *Value Health*. Oct 01, 2021. Epub ahead of print.
3. **Yeung K**, Zhu W, McCurry SM, Von Korff M, Wellman R, Morin CM, Vitiello MV. Cost-Effectiveness of Telephone Cognitive Behavioral Therapy for Osteoarthritis-Related Insomnia. *J Am Geriatr Soc*. 2022 Jan;70(1):188-199.
4. Vitiello MV, Zhu W, **Yeung K**, McCurry SM. Short-term Improvements in Insomnia or Pain Predict Long-term Improvements in Sleep, Pain, Depression, and Fatigue in Older Adults with Co-Morbid Osteoarthritis Pain and Insomnia. *Sleep*. 2021 Sept. Epub ahead of print.
5. **Yeung K**, Dusetzina SB, Basu A. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018. *JAMA Network Open*. 2021 Jun 1;4(6):e2113393.
6. Brouwer E, **Yeung K**, Barthold D, Hansen R. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in one mid-size integrated health system. *J Manag Care Spec Pharm*. 2021 Jun;27(6):732-742.
7. **Yeung K**, Dorsey CN, Mettert K. Effect of new Medicare enrollment on health, healthcare utilization, and cost: A scoping review. *J Am Geriatr Soc*. 2021 Aug;69(8):2335-2343.

8. **Yeung K**, Dusetzina SB. Prescription Drug Out-of-Pocket Cost Reduction Programs: Incentives and Implications. *JAMA Intern Med.* 2021 Jun 1;181(6):765-766. [Commentary]
9. Li M, **Yeung K**. Managing high-priced biologic agents: challenges and potential solutions. *J Manag Care Spec Pharm.* 2021 Mar;27(3):411-414. [Commentary]
10. McCurry SM, Zhu W, Von Korff M, Wellman R, Morin CM, Thakral M, **Yeung K**, Vitiello MV. Effect of Telephone Cognitive Behavioral Therapy for Insomnia in Older Adults with Osteoarthritis Pain: A Randomized Clinical Trial. *JAMA Intern Med.* 2021 Apr 1;181(4):530-538.
11. **Yeung K**, Richards J, Goemer E, Lozano P, Lapham G, Williams E, Glass J, Lee A, Achtmeyer C, Caldeiro R, Parrish R, Bradley K. Costs of Using Evidence-Based Implementation Strategies for Behavioral Health Integration in a Large Primary Care System. *Health Serv Res.* 2020 Dec;55(6):913-923.
12. **Yeung K**, Barthold D, Dusetzina S, Basu A. Patient and plan spending after state specialty drug out-of-pocket caps. *N Engl J Med.* 2020; 383:558-566.
13. Dieleman J, Cao J, Chapin A, Chen C, Li Z, Liu A, Horst C, Kaldjian A, Matyas T, Scott K, Bui A, Campbell M, Duber HC, Dunn AC, Flaxman AD, Fitzmaurice C, Naghavi M, Sadat N, Shieh P, Squires E, **Yeung K**, Murray CJL. US Health Care Spending by Payer and Health Condition, 1996-2016. *JAMA.* 2020;323(9):863-884.
14. Zhang J, Haynes K, Mendelsohn AB, Marshall J, Barr CE, McDermott C, Brown J, Kline A, Kenney J, King KJ, Holmes C, **Yeung K**, Barron J, Yun H, Lockhart CM. Capture of biologic and biosimilar dispensings in a consortium of U.S.-based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims. *Pharmacoepidemiol Drug Saf.* 2020 Jul;29(7):778-785.
15. McCurry SM, Von Korff M, Morin CM, Cunningham A, Pike KC, Thakral M, Wellman R, **Yeung K**, Zhu W, Vitiello MV. Telephone interventions for co-morbid insomnia and osteoarthritis pain: The OsteoArthritis and Therapy for Sleep (OATS) randomized trial design. *Contemp Clin Trials.* 2019 Oct 13;87:105851.
16. **Yeung K**, Morgan S. Should National Pharmacare Apply a Value-based Insurance Design? *CMAJ.* 2019 Jul 22;191(29): E811-E815.
17. Brouwer E, Basu A, **Yeung K**. Implicit Adoption of Cost-Effectiveness-driven Value-Based Formularies in Private Health Insurance 2010-2013. *PharmacoEconomics.* 2019 Oct;37(10):1287-1300.*
18. **Yeung K**. Value-based Insurance Design: Current Evidence and Future Directions. *J Manag Care Spec Pharm.* 2019 Jul;25(7):738-741.
19. Banegas MP, Rivera DR, O'Keeffe-Rosetti M, Carroll NM, Pawloski PA, Tabano DC, Epstein MM, **Yeung K**, Hornbrook MC, Lu C, Ritzwoller DP. Long-term Patterns of Oral Anti-Cancer Agent Adoption, Duration and Switching in Patients with CML. *J Natl Compr Canc Netw.* 2019 Oct 1;17(10):1166-1172.
20. **Yeung K**, Suh K, Garrison LP Jr, Carlson JJ. Defining and Managing High-Priced Cures: Healthcare Payers' Opinions. *Value Health.* 2019 Jun;22(6):648-655.
21. Khilfeh I, Guyette E, Watkins J, Danielson D, Gross D, **Yeung K**. Adherence, Persistence, and Expenditures for High Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study. *J Manag Care Spec Pharm.* 2019 Apr;25(4):461-467.*

22. **Yeung K**, Basu A, Hansen RN, Sullivan SD. Price elasticities of pharmaceuticals in a value-based-formulary setting. *Health Econ.* 2018 Nov;27(11):1788-1804.
(**Best Paper-Vancouver Health Economics Methodology Annual Meeting**)
23. **Yeung K**, Meng L, Carlson JJ Performance-Based Risk Sharing Schemes to Address Indication-Specific Uncertainty in Indication-Based Pricing. *J Manag Care Spec Pharm.* 2017 Oct; 23(10):1010-1015.
(**Best Paper of the Year**)
24. **Yeung K**, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholders' Perceptions of Policy Options to Address Affordability of Prescription Drugs. *J Manag Care Spec Pharm.* 2017 Oct;23(10):1084-1090.
25. **Yeung K**, Basu A, Marcum Z, Watkins JB, Sullivan SD. Impact of a Value-Based Formulary in Three Chronic Disease Cohorts. *Am J Manag Care.* 2017 March; 23(3 Suppl):S46-S53.
(**Challenge Prize Winner**)
26. Jelačić S, Craddick K, **Yeung K**, Bounthavong M, Nair B, Kusolos D, Bowdle A. Relative Costs of Anesthesiologist Prepared, Hospital Pharmacy Prepared and Outsourced Anesthesia Drugs. *J Clin Anesth.* 2017 Feb;36:178-183.
27. **Yeung K**, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a value-based formulary on medication utilization, health services utilization, and expenditures. *Med Care.* 2017 Feb;55(2):191-198.
28. Sullivan SD, **Yeung K**, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. *J Manag Care Spec Pharm.* 2015 Apr;21(4):269-75.
(**Honorable Mention Best Paper of the Year**)
29. Carlson JJ, Gries KS, **Yeung K**, Sullivan SD, Garrison LP Jr. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. *Appl Health Econ Health Policy.* 2014 Jun;12(3):231-8.
30. Gold LS, **Yeung K**, Smith N, Allen-Ramey FC, Nathan RA, Sullivan SD. Asthma control, cost and race: results from a national survey. *J Asthma.* 2013 Sep;50(7):783-90.
31. Vo AA, Petrozzino J, **Yeung K**, Sinha A, Kahwaji J, Peng A, Villicana R, Mackowiak J, Jordan SC. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. *Transplantation.* 2013 Mar 27;95(6):852-8.
32. Littlejohns P, **Yeung K**, Clark S, Weale A. A proposal for a new social values research program and policy network. *J Health Organ Manag.* 2012;26(3):407-21.
33. **Yeung K**, Carlson JJ. Clinical and economic review of erlotinib in non-small-cell lung cancer. *Expert Rev Pharmacoecon Outcomes Res.* 2012 Aug;12(4):411-23.
34. **Yeung K**. Using AHRQ's evidence-based reports to improve managed care pharmacy practice: oral antidiabetic agents. *J Manag Care Pharm.* 2011 Oct;17(8):641-9.
35. **Yeung K**, Miller JS, Savage AE, Husband BC, Iqic B, Kohn JR. Association of Ploidy and Sexual System in *Lycium californicum*. *Evolution.* 2005; 59(9):2048-2055.

Accepted peer-reviewed papers in press

1. Drummond M, Augustovski F, **Yeung K**. Challenges of Health Technology Assessment (HTA) in Pluralistic Health Care Systems. Value Health [in press]

Papers under review in peer-reviewed journals

1. Chavez L, Richards J, Fishman P, **Yeung K**, Renz A, Quintana L, Massimino S, Penfold R. Cost of implementing an evidence-based intervention to support safer use of antipsychotics in youth.

Published technical reports

1. **Yeung K**, Basu A. Health Policy Options for Washington State: Value-Based Insurance Design. Washington State Office of the Insurance Commissioner. June 2017

Published abstracts from professional conferences

- | | |
|---|------------|
| Yeung K Value-based Reference Pricing to Address Spending on Specialty Drugs Vancouver Health Economics Methodology (VanHEM), Annual Meeting | July 2019 |
| Yeung K , Tsiao E, Watkins J. Re-Designing a Value-Based Formulary to Address Current Pharmaceutical Spending Trends: Changes in Drug-Tier Classifications (Top 20% poster award) Academy of Managed Care Pharmacy Annual Meeting | March 2019 |
| Yeung K, Goemer E, Kim V State Policies to Address Specialty Drug Access AcademyHealth, Annual Research Meeting | June 2018 |
| Suh K, Basu A, Yeung K , Bansal A, Garrison LP, Carson JJ. Health impact framework for cures and high impact medical technologies International Society for Pharmacoeconomics and Outcomes Research Annual Meeting | May 2017 |
| Carlson JJ, Bansal A, Suh K, Yeung K , Garrison LP, Basu A. Health impact framework for cures and high impact medical technologies International Society for Pharmacoeconomics and Outcomes Research Annual Meeting | May 2017 |
| Yeung K , Kho T, Watkins JB. Systematic review of economic evidence grading systems: a payers' perspective. Academy of Managed Care Pharmacy Annual Meeting | April 2016 |
| Pistoresi RH, Yeung K , Danielson D, Watkins JB, Sullivan SD. An Analysis of the Decisions for a Value-based Formulary against its ICER Threshold Guidelines Academy of Managed Care Pharmacy Annual Meeting | April 2015 |
| Yeung K , Sullivan SD, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D Veenstra DL, Garrison LP, Burke W, Watkins JB. Improving the Value of Prescription Drug Insurance. Translational Science 2014 Annual Meeting | April 2014 |
| Yeung K , Gong C. Cost-utility analysis of enzalutamide vs. abiraterone for the treatment of docetaxel refractory metastatic castrate resistant prostate cancer. International Society for Pharmacoeconomics and Outcomes Research Annual Meeting | May 2013 |

- Yeung K, Hay J.** Cost-utility analysis of romiplostim versus splenectomy in the treatment of chronic refractory immune thrombocytopenic purpura. **(Best student poster award)**
Academy of Managed Care Pharmacy Annual Meeting April 2011
- Yeung K, Robinson M, Kowalski J.**
The Impact of Geographic Atrophy on Managed Care Organizations.
Academy of Managed Care Pharmacy Educational Conference April 2009
- Yeung K.**
NP/PA Clinics: Opportunity or Obstacle to the Future of Pharmacy?
California Society of Health System Pharmacy Annual Conference May 2008

INVITED PRESENTATIONS

- Yeung K** Jan 2022
A Framework for Thinking About Drug Affordability Policies
Oregon State Senate Committee on Healthcare
- Yeung K** Dec 2021
Impact of the Value-based Formulary-Essentials on Spending and Healthcare Use
University of Washington CHOICE Institute Seminar
- Yeung K, Dusetzina SB, Basu A.** June 2021
Association of Branded Drug Rebates and out-of-Pocket Costs, 2007-2018
The American Society of Health Economists Annual Meeting
- Yeung K** Oct 2020
Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018
University of Washington CHOICE Institute Seminar
- Yeung K, Drummond M, Augustovski F, Tsiao, E.** Health Technology Assessment in Pluralistic Health Care Systems: Challenges and Preliminary Lessons Learned May 2020
International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting
- Yeung K** Dec 2019
Findings from a Patient Shared Savings Simulation
University of Washington CHOICE Institute Seminar
- Yeung K.** Specialty Drug Access Laws: Impacts on Patient and Plan Financial Burden across the Distribution June 2019
American Society of Health Economists, Annual Meeting -Washington DC
- Yeung K** Dec 2018
Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps
University of Washington PHENOM Seminar
- Yeung K.** Impact of a Value-Based Formulary in Three Chronic Disease Cohorts Feb 2017
American Journal of Managed Care Cost-Sharing Roundtable-Washington DC
(PAN Challenge Prize Winner)
- Yeung K.** Implications of a Value-Based-Formulary for Healthcare Policy Makers June 2016

Washington State Prescription Drug Price and Purchasing Summit

Yeung K, Basu A, Hansen RN, Sullivan SD. Price Elasticities of Pharmaceuticals in a Value-Based-Formulary Setting June 2016
 Vancouver Health Economics Methodology (VanHEM), Annual Meeting
(Best student paper award)

Yeung K, McElwee N, Watkins J, Drummond M. Paying for Cures—How We Can Afford It? April 2016
 Academy of Managed Care Pharmacy, Annual Meeting

Yeung K, Basu A, Hansen RN, Watkins J, Sullivan SD. Application of Cost-Effectiveness Logic May 2015 to US Managed Care Drug Formularies: Long Term Outcomes of a Value-Based Formulary.
 International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting
(Best student podium presentation award)

Yeung K. Pharmacoeconomic Modeling: Applying Value to Formulary Management. April 2015
 Academy of Managed Care Pharmacy, Annual Meeting

Yeung K, Sullivan SD, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Incentivizing value in managed care drug formularies: design, implementation, and first-year outcomes of a value-based formulary. June 2014
 International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting
(Best student podium presentation award)